Syra Health Corp

SYRA
About the company

Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education and training, and healthcare workforce development and staffing in the United States.

Country: United StatesPrice: $0.75Market Cap: $10.6M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Graham, Lynch and Marks object

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2604 (Top 84.1%)PASSFAILFAILFAILFAILFAILFAILFAILFAILBUYFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-12

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 12✗ 3▾

    9 of 12 pass — Graham, Lynch and Marks object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.06, IC: 58.9x
    ✓BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.06
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities3.47
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.06
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.06
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-68.1x, D/EBITDA=N/A (D&A unavailable)
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.06
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0593; #1067/4210 (top 25.3%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Profitability0% pass✓ 11✗ 24▾

    No clean pass — all 16 investors flag at least one profitability criterion

    Net income / market capitalization+6.63%; #1259/6340 (top 19.9%)
    ✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive EPS (10 years)0/5 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/5 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-136.2%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-12.5% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE23.2%
    ✓Lynch> 15%
    EBIT / Enterprise Value-10.0%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-10.0%, ROC=-198.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-32.32%
    ✗PiotroskiROA > 0
    ROA Change YoY-102.17% -> -32.32% (delta: +69.85%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-16.15%, ROA=-32.32%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY20.7% -> 34.4%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity23.2%
    ✓Dreman> 12%
    Margin of SafetyP/B=4.2x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-82.2% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/4 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue6.8%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity23.2%
    ✓Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-52.4% (2023) -> -12.5% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 25.6% -> 34.4%, operating margin -52.4% -> -12.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Gross profit / total assets+90.26%; #177/3702 (top 4.8%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity+23.19%; #665/5226 (top 12.7%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.2742; #4528/5884 (top 77.0%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation0% pass✓ 2✗ 26▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Net income / market capitalization+6.63%; #1259/6340 (top 19.9%)
    ✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio4.2x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-10.0%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-10.0%, ROC=-198.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share4.2x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation Reasonableness
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-4.2%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=4.2x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low1183% of trailing low ($0.06)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Positive book equity / market capitalization+0.2858; #3754/6449 (top 58.2%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share4.21x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-24.2%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.8469; #1965/5247 (top 37.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-4.23%; #2917/4519 (top 64.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+112.92%; #285/6202 (top 4.6%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy
    ✗BuffettPositive and growing
    FCF Positive and Growing$-0.4M
    ✗LynchPositive and growing
    Operating Cash Flow$-0.4M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-16.15%, ROA=-32.32%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-4.2%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/4 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-5.1%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/4 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-0.4M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-4.23%; #2917/4519 (top 64.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 2✗ 11▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.70 (2022) -> $-0.08 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/4 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-1.8%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency3/3 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 25.6% -> 34.4%, operating margin -52.4% -> -12.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Verdicts13% pass✓ 2✗ 14▾

    Split decision: 13 FAIL · 1 PASS · 1 BUY · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (1/9)✗BuffettFAIL (2/9)✗LynchFAIL (3/7)✗GreenblattRank #2604✓PiotroskiPASS (F-Score 5)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)✓AsnessBUY (Rank #25/2370 (Top 1.1%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag SYRA's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio3.47
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-237.1%
    ✗Buffett> 10%
    ROIC - WACC-247.1%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-198.3%
    ✗Greenblatt> 25%
    Current Ratio Change YoY5.46 -> 4.06
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY2.17x -> 2.61x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities3.47
    ✓Dreman> 1.5
    Return on Invested Capital15.0%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-54.3%; FY2024: ROIC=-98.1%; FY2025: ROIC=-32.3%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/4 years above 12% (latest -32.3%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Business Services
Size: Micro Cap($10.6M)
Revenue: $7.2M-9.5% YoY
Net Income: $-896333.00+76.2% YoY

Financial Snapshot

Operating Margin-12.5%
Return on Equity-42.7%
Debt / Equity0.06
Current Ratio4.06
EPS (Diluted)$-0.08
Shares Retired−57.0% / −143.0% 2y

Similar Companies

ADPAUTOMATIC DATA PROCESSING INC
$122.3B
EAELECTRONIC ARTS INC.
$52.9B
RBRKRubrik, Inc.
$22.6B
ACMAECOM
$9.1B

Shareholder Return

Fiscal 2025

Issued 57.0% of shares last year, 143.0% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-12
FY 2024
Sources
  • 10-K · 2025-03-11
FY 2023
Sources
  • 10-K · 2024-03-25
FY 2022
Sources
  • 10-K · 2024-03-25
FY 2021
Sources
  • 10-K · 2024-03-25
Market Cap$10.6Mcurrent------$948.2Kest.$3.7Mest.$5.3Mest.$9.1Mest.--
Revenue$9.0M↑19%$2.6M↑52%$2.4M↑23%$2.3M↑22%$7.2M↓9%$8.0M↑45%$5.5M↓2%$5.6M--
Operating Income$606.9K↑148%$300.0K↑229%$251.6K↑498%$191.0K↑140%-$904.3K↑76%-$3.8M↓30%-$2.9M↓38%-$2.1M--
Net Income$701.3K↑155%$344.6K↑253%$250.2K↑493%$241.0K↑151%-$896.3K↑76%-$3.8M↓28%-$2.9M↓39%-$2.1M--
EPS (Diluted)--$0.02↑200%$0.02↑300%$0.02↑150%$-0.08↑84%$-0.50↑17%$-0.60↑14%$-0.70--
Gross Margin42.6%↑36%46.3%↑41%44.5%↑15%42.7%↑35%34.4%↑66%20.7%↓19%25.6%↑35%18.9%—
Operating Margin6.8%↑140%11.7%↑185%10.5%↑424%8.4%↑133%-12.5%↑73%-47.2%↑10%-52.4%↓41%-37.2%—
ROE23.2%↑140%———-42.7%↑67%-130.6%↓78%-73.2%↑75%-298.3%—
Total Debt$179.3K↓5%$179.3K↓5%$71.7K↓17%$62.0K↓17%$116.4K↓24%$152.9K↓17%$184.9K↓75%$750.6K--
Shareholders' Equity$3.0M↑37%$3.0M↑37%$2.6M↑9%$2.4M↓4%$2.1M↓27%$2.9M↓28%$4.0M↑465%$710.1K↑10036%-$7.1K
Current Ratio3.47↑14%3.47↑14%3.13↓4%2.48↓14%4.06↓26%5.46↑4%5.25↑469%0.92—
Debt / Equity0.06↓31%0.06↓31%0.03↓24%0.03↓14%0.06↑4%0.05↑15%0.05↓96%1.06—
Operating Cash Flow$685.8K↑284%$331.8K↑236%-$718.8K↓892%$1.4M↑761%-$447.7K↑85%-$2.9M↓6%-$2.8M↓23%-$2.2M--
Free Cash Flow---------$447.9K↑85%-$2.9M↓6%-$2.8M↓17%-$2.4M--

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Business Services

SYRA vs Peers — Financial Grading

Revenue$7.2MBottom 25%
Net Income$-896333.00Median
ROE-42.7%Bottom 25%
D/E0.06Top 25%
Op. Margin-12.5%Bottom 25%
Curr. Ratio4.06Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
AUTOMATIC DATA PROCESSING INCADP$122.3B$309.93$21.9B$4.4B73.2%0.8224.2%1.054/95/93/70/3F-Score 65/11
ELECTRONIC ARTS INC.EA$52.9B$209.70$7.5B$887.0M13.1%0.2215.4%1.051/94/94/70/3F-Score 66/11
Rubrik, Inc.RBRK$22.6B$109.88$1.3B$348.8M67.1%—-26.2%1.691/90/92/70/3F-Score 62/11
AECOMACM$9.1B$70.50$16.1B$561.8M22.5%1.096.4%1.141/93/93/71/3F-Score 82/11
COMMVAULT SYSTEMS INCCVLT$6.2B$152.07$1.2B$70.7M942.8%—6.3%1.951/92/94/70/3F-Score 66/11
WPP plcWPP$6.0B$27.79$18.2B$289.5M-8.5%1.942.8%0.891/92/91/70/3F-Score 32/11
VARONIS SYSTEMS INCVRNS$5.6B$48.94$623.5M$129.3M-21.6%0.76-23.5%1.971/90/91/70/3F-Score 51/11
ROBERT HALF INC.RHI$4.3B$42.00$5.4B$133.0M10.4%—1.4%1.532/95/91/70/3F-Score 52/11